uniQure Sees Unusually High Options Volume (NASDAQ:QURE)

uniQure N.V. (NASDAQ:QURE) was the recipient of unusually large options trading on Tuesday. Traders purchased 35,694 call options on the company. This represents an increase of 488% compared to the typical volume of 6,074 call options.

Analyst Upgrades and Downgrades

QURE has been the subject of a number of analyst reports. Mizuho raised their price objective on uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. The Goldman Sachs Group raised their price target on uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, June 18th. Barclays reduced their price target on shares of uniQure from $65.00 to $60.00 and set an “overweight” rating on the stock in a report on Thursday, July 30th. Leerink Partners increased their price objective on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Finally, Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective for the company in a research report on Wednesday, June 17th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $59.55.

Insiders Place Their Bets

In other uniQure news, CEO Matthew Kapusta sold 21,082 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $45.16, for a total value of $952,063.12. Following the completion of the sale, the chief executive officer owned 519,227 shares of the company’s stock, valued at $23,448,291.32. This represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.65% of the stock is owned by insiders.

Institutional Investors Weigh In On uniQure

A number of institutional investors have recently made changes to their positions in QURE. Avoro Capital Advisors LLC raised its position in shares of uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after acquiring an additional 1,705,556 shares in the last quarter. Orbimed Advisors LLC increased its stake in uniQure by 189.7% in the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after purchasing an additional 1,398,749 shares in the last quarter. Siren L.L.C. acquired a new position in uniQure during the first quarter worth $16,350,000. Fiera Capital Corp purchased a new stake in uniQure during the fourth quarter worth $18,390,000. Finally, SG Americas Securities LLC grew its holdings in uniQure by 1,107.3% in the first quarter. SG Americas Securities LLC now owns 776,604 shares of the biotechnology company’s stock valued at $12,697,000 after purchasing an additional 712,278 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported that AMT-130 slowed disease progression by 44% on the cUHDRS measure and 61% on Total Functional Capacity (TFC) at 48 months in high-dose patients. The company also highlighted 80% cUHDRS and 67% TFC slowing at 36 months among 15 high-dose patients. uniQure Announces Additional AMT-130 Data
• Positive Sentiment: The company said the FDA previously accepted the 36-month data as the basis for its submitted Biologics License Application under the accelerated approval pathway. uniQure also reported a dose-dependent treatment effect and generally manageable safety findings, supporting its view that AMT-130 remains on a potential path toward approval. UniQure Insists Huntington’s Drug Is Still on Track
• Neutral Sentiment: uniQure’s four-year results were based on small patient groups and comparisons with external natural-history controls. The company said missing data and survivor bias may have understated the treatment effect, while a post-hoc analysis using an older control dataset produced stronger results. These methodological issues leave investors assessing how regulators will view the evidence.
• Negative Sentiment: The key cUHDRS endpoint at 48 months showed 44% slowing but was not statistically significant (p=0.144), undermining confidence in the durability and reliability of AMT-130’s benefit. News coverage characterized the results as a clinical-trial miss, prompting a heavy selloff and likely increasing concerns about whether the FDA will accept the data for accelerated approval. Reuters Trial Results Report
• Negative Sentiment: Two investor law firms announced securities investigations and invited QURE shareholders to participate, adding legal and reputational pressure following the data disclosure. SBS Law Fraud Investigation Announcement

uniQure Stock Down 37.3%

Shares of NASDAQ QURE traded down $14.60 during trading hours on Tuesday, hitting $24.51. 29,594,048 shares of the stock were exchanged, compared to its average volume of 2,424,308. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. uniQure has a 12 month low of $8.73 and a 12 month high of $71.50. The firm has a fifty day moving average price of $44.57 and a 200-day moving average price of $33.25. The company has a market cap of $1.70 billion, a PE ratio of -6.11 and a beta of 0.94.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). The business had revenue of $5.84 million for the quarter, compared to analysts’ expectations of $5.45 million. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.During the same quarter in the prior year, the company posted ($0.69) EPS. On average, sell-side analysts expect that uniQure will post -3.82 EPS for the current year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) technology to deliver genetic material intended to address the underlying causes of disease, with research activities spanning neurological, neuromuscular, metabolic and cardiovascular conditions.

uniQure’s pipeline has included AMT-130, an investigational gene therapy for Huntington’s disease, as well as programs targeting other conditions such as amyotrophic lateral sclerosis and Fabry disease.